Literature DB >> 25335805

Lung involvement in children with lysinuric protein intolerance.

Sarah Valimahamed-Mitha1, Laureline Berteloot, Héloise Ducoin, Chris Ottolenghi, Pascale de Lonlay, Jacques de Blic.   

Abstract

BACKGROUND AND OBJECTIVES: Lysinuric protein intolerance (LPI) is a rare multisystemic metabolic disease. The objective of the study was to describe presentation and course of lung involvement in a cohort of ten children. PATIENTS AND METHODS: Retrospective review of patients followed at Necker-Enfants Malades University Hospital between 1980 and 2012 for a LPI. In patients with lung involvement, clinical data, chest radiographs, pulmonary function tests, bronchoalveolar lavages, and lung biopsies were analyzed. The first and last high-resolution computed tomography (HRCT) were also reviewed.
RESULTS: Lung involvement was observed in ten of 14 patients (71 %). Five patients had an acute onset of respiratory symptoms, three had a progressive onset and two were free of symptoms. During the period studied, six patients (60 %) died, all in a context of respiratory failure. Clinical presentation and course were highly variable, even in the same family. HRCT were performed in seven cases, showing in all cases an interstitial pattern and fibrosis in four. All ten patients had pulmonary alveolar proteinosis (PAP) confirmed by histopathological analysis. Five patients had pulmonary fibrosis (at biopsy and/or HRCT scan). Two patients underwent whole lung lavages, without efficiency.
CONCLUSION: PAP is a constant feature in children with LPI and lung involvement. Pulmonary fibrosis is frequent and these two pathologies may develop independently. This study shows the heterogeneity of presentation and outcome. Lung injury could be secondary to impaired phagocytic function and abnormal inflammatory and immune responses intrinsic to the SLC7A7 mutant phenotype. HRCT is recommended to detect lung involvement.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25335805     DOI: 10.1007/s10545-014-9777-5

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  28 in total

1.  A cluster of lysinuric protein intolerance (LPI) patients in a northern part of Iwate, Japan due to a founder effect. The Mass Screening Group.

Authors:  A Koizumi; Y Shoji; J Nozaki; A Noguchi; X E; M Dakeishi; T Ohura; K Tsuyoshi; W Yasuhiko; M Manabe; Y Takasago; G Takada
Journal:  Hum Mutat       Date:  2000-09       Impact factor: 4.878

Review 2.  Lysinuric protein intolerance (LPI): a multi organ disease by far more complex than a classic urea cycle disorder.

Authors:  Hélène Ogier de Baulny; Manuel Schiff; Carlo Dionisi-Vici
Journal:  Mol Genet Metab       Date:  2012-02-17       Impact factor: 4.797

3.  Haemophagocytosis by myeloid precursors in lysinuric protein intolerance.

Authors:  William C Gordon; Brenda Gibson; M T J Leach; Peter Robinson
Journal:  Br J Haematol       Date:  2007-04-30       Impact factor: 6.998

4.  Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene.

Authors:  D Torrents; J Mykkänen; M Pineda; L Feliubadaló; R Estévez; R de Cid; P Sanjurjo; A Zorzano; V Nunes; K Huoponen; A Reinikainen; O Simell; M L Savontaus; P Aula; M Palacín
Journal:  Nat Genet       Date:  1999-03       Impact factor: 38.330

Review 5.  Lysinuric protein intolerance: reviewing concepts on a multisystem disease.

Authors:  Gianfranco Sebastio; Maria P Sperandeo; Generoso Andria
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-02-09       Impact factor: 3.908

6.  Pulmonary manifestations in lysinuric protein intolerance.

Authors:  K Parto; E Svedström; M L Majurin; R Härkönen; O Simell
Journal:  Chest       Date:  1993-10       Impact factor: 9.410

7.  Pulmonary alveolar epithelial uptake of S-nitrosothiols is regulated by L-type amino acid transporter.

Authors:  Olivia M Granillo; Mulugu V Brahmajothi; Sheng Li; A Richard Whorton; S Nicholas Mason; Timothy J McMahon; Richard L Auten
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-04-25       Impact factor: 5.464

8.  Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intolerance.

Authors:  Laura M Tanner; Kirsti Näntö-Salonen; Harri Niinikoski; Timo Jahnukainen; Päivi Keskinen; Heikki Saha; Kristiina Kananen; Antero Helanterä; Martti Metso; Marjatta Linnanvuo; Kirsi Huoponen; Olli Simell
Journal:  J Pediatr       Date:  2007-06       Impact factor: 4.406

9.  In Lysinuric Protein Intolerance system y+L activity is defective in monocytes and in GM-CSF-differentiated macrophages.

Authors:  Amelia Barilli; Bianca Maria Rotoli; Rossana Visigalli; Ovidio Bussolati; Gian C Gazzola; Zamir Kadija; Giuseppe Rodi; Francesca Mariani; Maria Lorena Ruzza; Maurizio Luisetti; Valeria Dall'Asta
Journal:  Orphanet J Rare Dis       Date:  2010-11-26       Impact factor: 4.123

10.  Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.

Authors:  T Kitamura; N Tanaka; J Watanabe; S Kanegasaki; Y Yamada; K Nakata
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

View more
  10 in total

1.  CT features of diffuse lung disease in infancy.

Authors:  Paolo Toma; Aurelio Secinaro; Oliviero Sacco; Davide Curione; Renato Cutrera; Nicola Ullmann; Claudio Granata
Journal:  Radiol Med       Date:  2018-03-22       Impact factor: 3.469

2.  Inhaled Sargramostim Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric Protein Intolerance.

Authors:  Laura M Tanner; Johanna Kurko; Maaria Tringham; Heikki Aho; Juha Mykkänen; Kirsti Näntö-Salonen; Harri Niinikoski; Heikki Lukkarinen
Journal:  JIMD Rep       Date:  2016-10-26

Review 3.  Overview of symptoms and treatment for lysinuric protein intolerance.

Authors:  Atsuko Noguchi; Tsutomu Takahashi
Journal:  J Hum Genet       Date:  2019-06-18       Impact factor: 3.172

Review 4.  Pulmonary alveolarproteinosis in children.

Authors:  Andrew Bush; Rishi Pabary
Journal:  Breathe (Sheff)       Date:  2020-06

5.  Update on Lysinuric Protein Intolerance, a Multi-faceted Disease Retrospective cohort analysis from birth to adulthood.

Authors:  Wladimir Mauhin; Florence Habarou; Stéphanie Gobin; Aude Servais; Anaïs Brassier; Coraline Grisel; Célina Roda; Graziella Pinto; Despina Moshous; Fahd Ghalim; Pauline Krug; Nelly Deltour; Clément Pontoizeau; Sandrine Dubois; Murielle Assoun; Louise Galmiche; Jean-Paul Bonnefont; Chris Ottolenghi; Jacques de Blic; Jean-Baptiste Arnoux; Pascale de Lonlay
Journal:  Orphanet J Rare Dis       Date:  2017-01-05       Impact factor: 4.123

Review 6.  Amino Acid Transport Defects in Human Inherited Metabolic Disorders.

Authors:  Raquel Yahyaoui; Javier Pérez-Frías
Journal:  Int J Mol Sci       Date:  2019-12-23       Impact factor: 5.923

7.  Children with lysinuric protein intolerance: Experience from a lower middle income country.

Authors:  Syed Bilal Hashmi; Sibtain Ahmed
Journal:  World J Clin Pediatr       Date:  2022-07-09

8.  Immune Dysregulation Mimicking Systemic Lupus Erythematosus in a Patient With Lysinuric Protein Intolerance: Case Report and Review of the Literature.

Authors:  Josefina Longeri Contreras; Mabel A Ladino; Katherine Aránguiz; Gonzalo P Mendez; Zeynep Coban-Akdemir; Bo Yuan; Richard A Gibbs; Lindsay C Burrage; James R Lupski; Ivan K Chinn; Tiphanie P Vogel; Jordan S Orange; M Cecilia Poli
Journal:  Front Pediatr       Date:  2021-05-20       Impact factor: 3.418

9.  Downregulation of SLC7A7 Triggers an Inflammatory Phenotype in Human Macrophages and Airway Epithelial Cells.

Authors:  Bianca Maria Rotoli; Amelia Barilli; Rossana Visigalli; Filippo Ingoglia; Marco Milioli; Maria Di Lascia; Benedetta Riccardi; Paola Puccini; Valeria Dall'Asta
Journal:  Front Immunol       Date:  2018-03-19       Impact factor: 7.561

10.  Inducible Slc7a7 Knockout Mouse Model Recapitulates Lysinuric Protein Intolerance Disease.

Authors:  Susanna Bodoy; Fernando Sotillo; Meritxell Espino-Guarch; Maria Pia Sperandeo; Aida Ormazabal; Antonio Zorzano; Gianfranco Sebastio; Rafael Artuch; Manuel Palacín
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.